NMN (Nicotinamide Mononucleotide)


NAD+ precursor

A direct precursor of NAD+ and the molecule directly downstream of NAMPT, the rate-limiting enzyme of NAD+ salvage; popularized by David Sinclair for longevity applications.

Abstract

NMN (ฮฒ-nicotinamide mononucleotide; CAS 1094-61-7; molecular formula C11H15N2O8P; molecular weight 334.22) is the immediate precursor of NAD+ in the salvage biosynthesis pathway, generated by phosphorylation of nicotinamide riboside by NRK kinases or by NAMPT-mediated condensation of nicotinamide with PRPP. NMN was popularized by David Sinclair’s group at Harvard as a longevity supplement for raising NAD+ levels, which decline with age. The compound is converted to NAD+ through NMNAT enzymes after cell uptake (presumed via Slc12a8 transporter or via dephosphorylation to NR with separate uptake). Animal studies show NMN supplementation reverses several age-related phenotypes (vascular, metabolic, neurological) by restoring NAD+ levels. Human clinical trials have shown plasma NAD+ elevation but clinical endpoint changes are modest. The compound is sold as a dietary supplement; FDA classified NMN as a drug investigation in 2022, complicating supplement market availability.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph